Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Roti

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Haematologica|February 27, 2025
<i>Ex vivo</i> drug response profiling guides therapy in a case of high-risk acute undifferentiated leukemia with <i>PICALM::MLLT10</i>Elena Mastrodicasa, Luca Pagliaro, Valentina Pierini, et al.
Genes, Chromosomes & Cancer|February 21, 2021
MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemiaValentina Bardelli, Silvia Arniani, Valentina Pierini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2024
Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLCGiulia Mazzaschi, Cristina Marrocchio, Lucas Moron Dalla Tor, et al.
The Journal of Clinical Investigation|February 14, 2012
The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemiaVersha Banerji, Stacey M Frumm, Kenneth N Ross, et al.
Hemasphere|March 11, 2024
<i>Myb</i> overexpression synergizes with the loss of <i>Pten</i> and is a dependency factor and therapeutic target in T-cell lymphoblastic leukemiaAndré Almeida, Sara T'Sas, Luca Pagliaro, et al.
Blood|May 19, 2026
Inhibition of the Atypical Kinase WNK1 as a Therapeutic Strategy in TAL-related T-cell Acute Lymphoblastic LeukemiaAnna Montanaro, Gregorio Monica, Raffaella Zamponi, et al.
Cancer Cell|December 12, 2018
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer RemodelingAmanda Balboni Iniguez, Gabriela Alexe, Emily Jue Wang, et al.
Cell Death & Disease|June 17, 2022
Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemiaAnna Montanaro, Samuel Kitara, Elisa Cerretani, et al.
Cell Chemical Biology|May 11, 2020
Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic LeukemiaMatteo Marchesini, Andrea Gherli, Anna Montanaro, et al.
Haematologica|April 1, 2025
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Haematologica|February 27, 2025
<i>Ex vivo</i> drug response profiling guides therapy in a case of high-risk acute undifferentiated leukemia with <i>PICALM::MLLT10</i>Elena Mastrodicasa, Luca Pagliaro, Valentina Pierini, et al.
Genes, Chromosomes & Cancer|February 21, 2021
MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemiaValentina Bardelli, Silvia Arniani, Valentina Pierini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2024
Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLCGiulia Mazzaschi, Cristina Marrocchio, Lucas Moron Dalla Tor, et al.
The Journal of Clinical Investigation|February 14, 2012
The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemiaVersha Banerji, Stacey M Frumm, Kenneth N Ross, et al.
Hemasphere|March 11, 2024
<i>Myb</i> overexpression synergizes with the loss of <i>Pten</i> and is a dependency factor and therapeutic target in T-cell lymphoblastic leukemiaAndré Almeida, Sara T'Sas, Luca Pagliaro, et al.
Blood|May 19, 2026
Inhibition of the Atypical Kinase WNK1 as a Therapeutic Strategy in TAL-related T-cell Acute Lymphoblastic LeukemiaAnna Montanaro, Gregorio Monica, Raffaella Zamponi, et al.
Cancer Cell|December 12, 2018
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer RemodelingAmanda Balboni Iniguez, Gabriela Alexe, Emily Jue Wang, et al.
Cell Death & Disease|June 17, 2022
Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemiaAnna Montanaro, Samuel Kitara, Elisa Cerretani, et al.
Cell Chemical Biology|May 11, 2020
Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic LeukemiaMatteo Marchesini, Andrea Gherli, Anna Montanaro, et al.
Haematologica|April 1, 2025
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
Pageof 8